ASX has got this completely wrong - this is price sensitive 100%. Brilliant news, Ovarian CA's historical trials can now be ticked off as validated and further, genuine advantage over other standard of care treatments like cisplatin, doxorubicin and epirubicin is shown. Maybe the ASX too thinks these validation pre-clinical trials are a required, but redundant tick box exercise. More news to come... GLTA
Ann: Positive Early Preclinical Ovarian Cancer Results, page-8
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |